NASH (non‑alcoholic steatohepatitis) and Fatty Liver Slide Library

Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD) and heart failure. Uncover the paramount importance of comprehending the

Explore with the slides the significance of a multistakeholder approach in NAFLD care as it tackles the complexities of comorbidities, patient detection, and groundbreaking tactics to enhance treatment results and

Dr. Kwanten (Belgium) discusses the role of pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and

Dr. Castera discusses how clinicians can integrate NASH assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient for improved patient

Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented when indicated. Hepatocellular carcinoma is rare in patients with NASH

The best treatment for NASH still remains as caloric intake reduction, weight loss, exercise and no heavy alcohol consumption, but these are merely lifestyle changes. There appears to be a

Several cognitive and psychological factors influence behavioral change and weight loss success. Most patients with NAFLD have adverse cognitive-behavioral profiles and 20-25% have co-existing mental illness. Without targeted intervention, behavior

NASH with severe fibrosis is more prevalent than one may think. Hispanics and those with type 2 DM are at a higher risk, however other ethnic groups with risk factors

It was found that the natural history of NAFLD is variable. Whilst 31% of patients with NAFLD develop NASH, 29% of patients have been found to resolve it. The fibrosis